Personalized Medicine in Early Stage Colorectal Cancer: Organ Preservation and Immune Benefit

Not yet recruitingOBSERVATIONAL
Enrollment

310

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Colorectal Cancer
Interventions
DIAGNOSTIC_TEST

Immunoscore Colon Test

"Immunoscore Colon is an in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer.~The test uses immunohistochemistry, digital pathology techniques and a dedicated image analysis software to determine CD3+ and CD8 + cell densities in the tumor ant in the invasive margin of the tumor."

Trial Locations (1)

75015

AP-HP - hôpital européen Georges-Pompidou, Paris

All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

collaborator

Ministry of Health, France

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06251726 - Personalized Medicine in Early Stage Colorectal Cancer: Organ Preservation and Immune Benefit | Biotech Hunter | Biotech Hunter